{"filing":{"accession_number":"0001640334-26-001468","cik":"0001348362","ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-07","primary_document":"lxrp_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001468/lxrp_8k.htm"},"events":[{"id":32279,"run_id":29656,"accession_number":"0001640334-26-001468","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Lexaria entered into inducement agreements whereby warrant holders exercised existing warrants at a reduced price and received new unregistered Series A and Series B warrants as consideration, raising approximately $5.9 million in gross proceeds. The new warrants, issued pursuant to Section 4(a)(2) and Rule 506 exemptions, are unregistered equity securities that create material dilution to existing shareholders.","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35418,"accession_number":"0001640334-26-001468","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Lexaria entered into inducement agreements whereby warrant holders exercised existing warrants at a reduced price ($12.92 vs. original prices of $17.85–$45.90) and received new unregistered Series A and Series B warrants as consideration. This transaction raises approximately $5.9 million in gross proceeds and involves the issuance of new unregistered equity securities (the New Warrants), which is characteristic of a dilutive capital raise. While the primary mechanism is warrant exercise rather than a direct equity issuance, the inducement structure—offering new warrants to incentivize early exercise—is economically equivalent to a dilutive private placement and would materially affect a reasonable investor's assessment of share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35419,"accession_number":"0001640334-26-001468","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of Series A and Series B warrants to purchase 453,969 shares of common stock each, issued in connection with the exercise of existing warrants for approximately $5.9 million in gross proceeds. The New Warrants are being offered pursuant to Section 4(a)(2) and Rule 506 exemptions to accredited investors and have not been registered under the Securities Act. This is a classic dilutive equity issuance raising capital through warrant exercises and new warrant grants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35420,"accession_number":"0001640334-26-001468","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the exercise of outstanding warrants for approximately $5.9 million in gross proceeds, with the Company issuing new unregistered Series A and Series B warrants to warrant holders as consideration. The new warrants are being offered in a private placement and have not been registered under the Securities Act, creating dilution to existing shareholders. This is a classic warrant exercise transaction that raises capital through dilutive equity issuance, even though the immediate proceeds come from warrant exercise rather than a direct equity sale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35418,"accession_number":"0001640334-26-001468","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Lexaria entered into inducement agreements whereby warrant holders exercised existing warrants at a reduced price ($12.92 vs. original prices of $17.85–$45.90) and received new unregistered Series A and Series B warrants as consideration. This transaction raises approximately $5.9 million in gross proceeds and involves the issuance of new unregistered equity securities (the New Warrants), which is characteristic of a dilutive capital raise. While the primary mechanism is warrant exercise rather than a direct equity issuance, the inducement structure—offering new warrants to incentivize early exercise—is economically equivalent to a dilutive private placement and would materially affect a reasonable investor's assessment of share dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-09"},{"id":35419,"accession_number":"0001640334-26-001468","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of Series A and Series B warrants to purchase 453,969 shares of common stock each, issued in connection with the exercise of existing warrants for approximately $5.9 million in gross proceeds. The New Warrants are being offered pursuant to Section 4(a)(2) and Rule 506 exemptions to accredited investors and have not been registered under the Securities Act. This is a classic dilutive equity issuance raising capital through warrant exercises and new warrant grants.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-09"},{"id":35420,"accession_number":"0001640334-26-001468","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the exercise of outstanding warrants for approximately $5.9 million in gross proceeds, with the Company issuing new unregistered Series A and Series B warrants to warrant holders as consideration. The new warrants are being offered in a private placement and have not been registered under the Securities Act, creating dilution to existing shareholders. This is a classic warrant exercise transaction that raises capital through dilutive equity issuance, even though the immediate proceeds come from warrant exercise rather than a direct equity sale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T14:12:45.309205+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-09-09"}]}